- Previous Close
0.6100 - Open
0.5350 - Bid --
- Ask --
- Day's Range
0.4535 - 0.5500 - 52 Week Range
0.3000 - 5.3700 - Volume
4,911,089 - Avg. Volume
9,440,382 - Market Cap (intraday)
3.181M - Beta (5Y Monthly) 1.22
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0500 - Earnings Date Nov 18, 2024 - Nov 21, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
www.mtem.comRecent News: MTEM
View More
Performance Overview: MTEM
Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MTEM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MTEM
View MoreValuation Measures
Market Cap
4.02M
Enterprise Value
2.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.15
Price/Book (mrq)
0.56
Enterprise Value/Revenue
0.12
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-61.35%
Return on Assets (ttm)
-37.88%
Return on Equity (ttm)
--
Revenue (ttm)
25.47M
Net Income Avi to Common (ttm)
-15.63M
Diluted EPS (ttm)
-3.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
9.66M
Total Debt/Equity (mrq)
155.07%
Levered Free Cash Flow (ttm)
-17.5M
Research Analysis: MTEM
View MoreCompany Insights: MTEM
MTEM does not have Company Insights
Research Reports: MTEM
View MoreDaily – Vickers Top Buyers & Sellers for 04/05/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 07/20/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/11/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 09/24/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.